highly significantP < 0.00001
Conversely, for mortality outcomes, the combined effect for stage I–IV HR+ breast cancer was highly significant, demonstrating a 23% reduction in overall mortality risk (HR = 0.77, 95% CI: 0.73–0.81, P < 0.00001).
Conversely, for mortality outcomes, the combined effect for stage I–IV HR+ breast cancer was highly significant, demonstrating a 23% reduction in overall mortality risk (HR = 0.77, 95% CI: 0.73–0.81, P < 0.00001).